---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-25-000006"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:15:44.843042+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers

## Summary
- First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).
- Trial targets CLDN6-positive advanced/metastatic ovarian, endometrial, and testicular cancers.
- Study expected to enroll up to 70 patients; initial data anticipated first half of 2026.
- CEO Martin Lehr highlights the milestone as key pipeline advancement.
- Company presented at SITC 2024 supporting first-in-human dose selection.

## SEC filing metadata
- accession: 0001842952-25-000006
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/0001842952-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/cntx-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-25-000006
- JSON: https://secwatch.observer/filing/0001842952-25-000006.json
- Plain text: https://secwatch.observer/filing/0001842952-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.